22 Papers
57 Citations
D. Kim is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 7, co-authored 21 publications. Previous affiliations of D. Kim include New Generation University College.
Chat about Author
Papers
Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1
D. Kim,Ranee Mehra,D.S.W. Tan,Enriqueta Felip,Laura Q.M. Chow,D.R. Camidge,Johan Vansteenkiste,Sunil Sharma,T. De Pas,G. J. Riely,Ben Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,G. Liu,Armando Santoro,Margarida Geraldes,Anthony Boral,A. Yovine,Alice T. Shaw +19 more
21
OA11.05 Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)
Se Hyun Kim,Yu Jung Kim,Chan Young Ock,Min Jung Kim,Bhumsuk Keam,Tae Min Kim,D. Kim,Dae Seog Heo,Jung-Gon Lee +8 more
TL;DR: Advanced stage and thymic carcinoma were found to be associated with worsened CSS, which is consistent with previous studies, and improvement in CSS trended towards significance in patients with remoteThymic neoplasms treated with chemoradiation.
13
The risk of newly developed visual impairment in treated normal-tension glaucoma: 10-year follow-up.
Yun J.eong Choi,Yun J.eong Choi,Martha Kim,Ki Ho Park,Ki Ho Park,D. Kim,D. Kim,Seok Hwan Kim,Seok Hwan Kim +8 more
TL;DR: To investigate the risk and risk factors for newly developed visual impairment in treated patients with normal‐tension glaucoma (NTG) followed up on for 10 years, a large number of patients were diagnosed with NNTG.
12
MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up
Yi-Long Wu,Y. Cheng,Jiaojiao Zhou,Shun Lu,Yinglin Zhang,Jing Zhao,D. Kim,Ross A. Soo,S-W. Kim,Hongming Pan,Yi Ming Arthur Chen,C. Chian,Xiaoqing Liu,D. Tan,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,K. Park,J.C.-H. Yang +19 more
8
OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC
Jessica Lin,D. Kim,A. Drilon,Robert C. Doebele,J.W. Lee,Viola W. Zhu,M-J. Ahn,J. Lim,Shanna Stopatschinskaja,J. Jean Cui,David M. Hyman,R. Camidge,S-H.I. Ou,Alice T. Shaw,Byoung Chul Cho +14 more
8